Clinical trials recruiting in Trois-Rivières, Canada

Phase breakdown

Conditions recruiting in Trois-Rivières, Canada

Recruiting trials in Trois-Rivières, Canada

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  NCT06747949 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
  NCT05417516 · Phase: Phase 3 · Ages: 50 Years to 120 Years · Sex: Female
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
  NCT07112339 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
  NCT06345729 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
  NCT06807424 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
  NCT07276581 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  NCT07082738 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
  NCT06991257 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female)
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  NCT06935370 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
  NCT06424288 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
  NCT06641089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
  NCT06623461 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
  NCT07186101 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
  NCT07226765 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
  NCT07225686 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  NCT06357533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
  NCT04797299 · Phase: Not specified · Ages: 46 Years and older · Sex: Female
• Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
  NCT05866458 · Phase: Not specified · Ages: 50 Years and older · Sex: Female
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
  NCT07175428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
  NCT06865105 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
  NCT07486960 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
  NCT02573636 · Phase: Not specified · Ages: 18 Years and older · Sex: Male
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
  NCT07181109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Trois-Rivières, Canada?

44 recruiting trials have at least one study site in Trois-Rivières, Canada.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.